DXR Insider Trading Activity and SEC Form 4 Filings
DXR insider trading summary
Over the past 12 months, insiders at Daxor Corp (DXR) reported 7 open-market purchases worth $19K by 4 insiders and no sales on SEC Form 4. Net insider buying was $19K.
Latest DXR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 8, 2026 | Michael Richard Feldschuh | Chief Executive Officer | Buy | $9K (1,000 @ $9.07) |
| Mar 31, 2026 | Robert J Michel | Chief Financial Officer | Buy | $10K (1,000 @ $9.90) |
| Mar 20, 2026 | John Jefferies | Chief Medical Officer | Buy | $0 (3,656 @ $0.00) |
| Mar 20, 2026 | John Jefferies | Chief Medical Officer | Buy | $0 (2,285 @ $0.00) |
| Dec 9, 2025 | Jonathan Adam Feldschuh | Chief Scientific Officer | Buy | $0 (18,000 @ $0.00) |
| Dec 9, 2025 | Robert J Michel | Chief Financial Officer | Buy | $0 (3,000 @ $0.00) |
| Nov 12, 2025 | John Jefferies | Chief Medical Officer | Buy | $0 (2,344 @ $0.00) |
| Apr 4, 2025 | Michael Richard Feldschuh | Chief Executive Officer | Buy | $16K (2,063 @ $7.89) |
| Mar 10, 2025 | Robert J Michel | Chief Financial Officer | Buy | $8K (1,000 @ $8.00) |
| Mar 10, 2025 | Michael Richard Feldschuh | Chief Executive Officer | Buy | $26K (3,360 @ $7.68) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.